PD-1/PD-L1

PD-1/Programmed death-ligand 1

PD-1/PD-L1

Related Products

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.

PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.

PD-1/PD-L1 Related Products (298)
Antibodies (8)

By Effects:	Control (1) Inhibitors (234) Ligands (3) Agonists (2) Degraders (5) Antagonists (5) Activators (6) Modulators (4) Inducers (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-151066

BMS-1233	Inhibitor
BMS-1233 is an orally active inhibitor for programmed cell death-ligand 1 (PD-L1), with IC₅₀ of 14.5 nM. BMS-1233 promotes cell death of HepG2 in a Jurkat T cell and HepG2 cell co-culture model, exhibits antitumor activity against melanoma in mouse model.

HY-P4072

(D)-PPA 1	Inhibitor
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy.

HY-169365

2-Methylbiphenyl-oxadiazole-NH-Ph-CHO	Ligand
2-Methylbiphenyl-oxadiazole-NH-Ph-CHO is the PD-L1 ligand part of AUTAC PD-L1 degrader-3 (HY-169363). 2-Methylbiphenyl-oxadiazole-NH-Ph-CHO can be utilized in AUTAC synthesis.

HY-P990716

Sabestomig
Sabestomig is an anti-PDCD1/HAVCR2 Ig(G1-κ G1-λ2) monoclonal antibody.

HY-162644

Antitumor agent-170	Inhibitor
Antitumor agent-170 (Compound C6) exhibits inhibitory activities against PD-1/PD-L1 interaction and PARP7, with IC₅₀ of 0.342 μM and 7.05 nM. Antitumor agent-170 exhibits a high affinity to human PD-L1, with a K_i of 9.31 nM. Antitumor agent-170 restores the T cell function and increases IFN-γ secretion. Antitumor agent-170 exhibits antitumor efficacy against melanoma in mouse models and good pharmacokinetic characteristics.

HY-P99679

Izuralimab	Inhibitor
Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1.

HY-161518

PD-1/PD-L1-IN-44	Inhibitor
PD-1/PD-L1-IN-44 (Compound 22) selectively inhibits PD-1/PD-L1 proteins (IC₅₀=1.21 nM). PD-1/PD-L1-IN-44 inhibits tumor growth without toxicity in animal models and increases CD8⁺ cell infiltration.

HY-167840

IMMH-010 maleate	Inhibitor
IMMH-010 maleate is a prodrug that serves as a novel PD-L1 inhibitor, exhibiting potential antitumor activity for the treatment of neurological disorders and advanced malignant solid tumors. IMMH-010 maleate is rapidly converted to its active form, YPD-29B, following oral administration. IMMH-010 maleate is poised for advancing research in the field of PD-L1 inhibitors and related therapeutic applications.

HY-P99723

Manelimab
Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1).

HY-172396

PD-L1/VISTA-IN-2	Inhibitor
PD-L1/VISTA-IN-2 (Compound S8) is an orally active bifunctional PD-L1/VISTA inhibitor with an IC₅₀ of 1.4 μM for PD-L1 and a K_D of 2.1 μM for VISTA. PD-L1/VISTA-IN-2 can activate the tumor immune microenvironment and exert anti-cancer effects.

HY-P990169

Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)	Inhibitor
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279. Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) can be used in WB and FC experiments in the context of human and mouse.

HY-156085

LP23	Inhibitor
LP23 is a non-arylmethylamine PD-1/PD-L1 inhibitor (IC₅₀: 16.7 nM) with anti-tumor activity. LP23 restores immune cell function in HepG2/Jurkat T cells and promotes HepG2 cell death. LP23 is active in vivo in the B16-F10 tumor model (TGI=88.6% at 30 mg/kg).

HY-P990824

Anti-Mouse PD-1 Antibody (J43)	Inhibitor
Anti-Mouse PD-1 Antibody (J43) is a kind of Armenian hamster IgG in vivo mouse antibody, targeting to PD-1. The recommend isotype control of Anti-Mouse PD-1 Antibody (J43): Armenian hamster IgG, Isotype Control (HY-P990305).

HY-156149

CYP51/PD-L1-IN-1	Inhibitor
CYP51/PD-L1-IN-1 (compound L11) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-1 is a dual inhibitor of CYP51 (IC₅₀: 0.884 μM) and PD-L1 (IC₅₀: 0.083 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-1 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death.

HY-162357

PD-L1-IN-5	Inhibitor
PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor, with the IC₅₀ value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo.

HY-155115

LSD1-IN-27	Inhibitor	98.88%
LSD1-IN-27 (Compound 5ac) is a LSD1 inhibitor (IC₅₀: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer.

HY-N0460R

1-Caffeoylquinic acid (Standard)	Inhibitor
1-Caffeoylquinic acid (Standard) is the analytical standard of 1-Caffeoylquinic acid. This product is intended for research and analytical applications. 1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with K_i of 0.007 μM. 1-Caffeoylquinic acid has anti-oxidative stress ability. 1-Caffeoylquinic acid is the inhibitor for PD-1/PD-L1.

HY-159892

PD-1/PD-L1-IN-54	Inhibitor
PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic PD-1/PD-L1 inhibitor (K_D: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC₅₀: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8⁺ T cells, upregulating PD-1 expression, and increasing secretion of IFN-γ and IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates T cell immunity through the PI3K/Akt pathway correlated with PD-1/PD-L1.

HY-144746

PD-1/PD-L1-IN-26	Inhibitor
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of PD-1/PD-L1 with an IC₅₀ of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases.

HY-163844

PD-1/PD-L1-IN-49	Inhibitor
PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1, with the IC₅₀ of 77 nM. PD-1/PD-L1-IN-49 activates Jurkat T cells, reflecting successful blockade of the PD-1/PD-L1 immune checkpoint.

Name
Email *

	Sorry, but the email address you supplied was invalid.

PD-1/PD-L1

PD-1/PD-L1

PD-1/PD-L1 Related Products (298)

Antibodies (8)

PD-1/PD-L1 Related Products (298):